L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease
Glasgow, G.L.; Henley, J.W.; Willoughby, E.W.
Australian and New Zealand Journal of Medicine 4(4): 373-378
1974
ISSN/ISBN: 0004-8291 PMID: 4278910 Document Number: 76045
Clinical experience with the use of L-alpha-methyldopa hydrazine (Carbidopa), an inhibitor of peripheral decarboxylation of L-dopa, in the treatment of idiopathic Parkinson's disease in twenty-six patients is described. Malaise, nausea and vomiting associated with L-dopa therapy were relieved in most patients. Improved motor function was marked in 25%, moderate in 50% of the patients, while the necessary dosage of L-dopa was reduced by a mean of 65%.